If you have heard about Ozempic or Wegovy in the past few years, you may not realize those drugs belong to a class that has been in clinical use since 2010, built on a molecule called liraglutide. The natural question is whether the original version is still relevant now that once-weekly alternatives dominate the headlines.

Osteoporosis drugs have a reputation problem. Most people picture them as bone-preserving at best — slowing breakdown, not adding new tissue. That impression is accurate for bisphosphonates, which is exactly why a second FDA-approved anabolic peptide often surprises people. If your doctor mentioned abaloparatide, your first questions are probably: Is this just another version of